Japanese drug major Takeda Pharmaceutical (TYO: 4502) has announced what it calls a ‘transformational pharmaceutical sciences partnership.’
As part of the new partnership agreement with Bushu Pharmaceuticals, an independent contract manufacturing organization (CMO), Takeda will transfer a part of its pharmaceutical sciences/chemistry, manufacturing and controls (CMC) business to the Saitama-based firm.
"This partnership will be our important cornerstone of globalization"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze